AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15622015 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients with mood fluctuations
Number of subjects: 87
Study 15622015 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients with anxiety fluctuations
Number of subjects: 87
Study 15622015 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients with motor fluctuations
Number of subjects: 87
Study 15622015 — intervention group
Group type: COMPARATOR
Intervention: Non-fluctuators
Number of subjects: 87
Study 11528549 — intervention group
Group type: EXPERIMENTAL
Intervention: Study AML-BFM-93-OST
Number of subjects: 262
Study 9780942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment approach
Number of subjects: 50
Study 9780942 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling combined with different occlusal treatments
Number of subjects: 50
Study 9780942 — intervention group
Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 50
Study 9780942 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of stress
Number of subjects: 50
Study 8091318 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD2138 (350 mg)
Number of subjects: 7
Study 8091318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3377456 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of cefodizime
Number of subjects: 424
Study 3377456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cefodizime
Number of subjects: 424
Study 3377456 — intervention group
Group type: COMPARATOR
Intervention: 1 g of cefotaxime
Number of subjects: 424
Study 3377456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 424
Study 3377456 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 424
Study 24626145 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephony intervention
Number of subjects: 108
Study 31754065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally 24 hours prior to procedure and misoprostol 400 μg buccally 2 hours before procedure
Number of subjects: 49
Study 31754065 — intervention group
Group type: COMPARATOR
Intervention: Osmotic dilators inserted 24 hours prior to procedure
Number of subjects: 49
Study 31754065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 49
Study 28446028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation Group (NSG)
Number of subjects: 79
Study 28446028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation Psychomotor Rehabilitation Program Group (NSPRG)
Number of subjects: 79
Study 28446028 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 79
Study 23536236 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary perspectives intervention with community involvement (MPI&CI)
Number of subjects: 40
Study 23536236 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 40
Study 24284150 — intervention group
Group type: EXPERIMENTAL
Intervention: QIRC strategy including workshops, access to opinion leaders, intraoperative demonstrations, postoperative questionnaires, and audit and feedback.
Number of subjects: 56
Study 24284150 — intervention group
Group type: EXPERIMENTAL
Intervention: QIRC strategy (experimental arm)
Number of subjects: 56
Study 21272400 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP diet
Number of subjects: 72
Study 21272400 — intervention group
Group type: COMPARATOR
Intervention: SMP diet
Number of subjects: 72
Study 21272400 — intervention group
Group type: COMPARATOR
Intervention: SSMP diet
Number of subjects: 72
Study 19296257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 115
Study 19296257 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 115
Study 16499517 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 1014
Study 16499517 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1014
Study 15156528 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (fish oil supplements) - 1.8 g of EPA and 1.2 g of DHA daily for 2 years
Number of subjects: 0
Study 11720074 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide/petrolatum diaper
Number of subjects: 268
Study 11720074 — intervention group
Group type: COMPARATOR
Intervention: Control diaper (identical except for absence of ZnO/Pet)
Number of subjects: 268
Study 9386869 — intervention group
Group type: EXPERIMENTAL
Intervention: TOR60 (60 mg daily)
Number of subjects: 463
Study 9386869 — intervention group
Group type: EXPERIMENTAL
Intervention: TOR240 (240 mg daily)
Number of subjects: 463
Study 9386869 — intervention group
Group type: COMPARATOR
Intervention: TAM40 (40 mg daily)
Number of subjects: 463
Study 8197648 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) alone
Number of subjects: 35
Study 8197648 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of papaverine, phentolamine, and PGE1
Number of subjects: 35
Study 3046409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bricanyl Turbuhaler (BT)
Number of subjects: 9
Study 3046409 — intervention group
Group type: COMPARATOR
Intervention: Metered Dose Inhaler (MDI) Bricanyl
Number of subjects: 9
Study 29664899 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional follow-up arm
Number of subjects: 4595
Study 29664899 — intervention group
Group type: COMPARATOR
Intervention: Universal follow-up arm
Number of subjects: 4595
Study 28344102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide in patients with liver metastases
Number of subjects: 204
Study 28344102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide in patients with lung metastases only
Number of subjects: 204
Study 28344102 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) in patients with liver metastases
Number of subjects: 204
Study 28344102 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) in patients with lung metastases only
Number of subjects: 204
Study 26282650 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (1,000 mg)
Number of subjects: 175
Study 26282650 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 175
Study 25098075 — intervention group
Group type: EXPERIMENTAL
Intervention: Movie-based simulation training (group B, n = 30)
Number of subjects: 90
Study 25098075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of movie-based simulation training and traditional verbal training (group A, n = 30)
Number of subjects: 90
Study 25098075 — intervention group
Group type: COMPARATOR
Intervention: Traditional verbal training alone (group C, n = 30)
Number of subjects: 90
Study 21150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (continuous infusion 0.25 mcg/kg · min)
Number of subjects: 50
Study 21150850 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (bolus dose 2.0 mcg/kg)
Number of subjects: 50
Study 18332291 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-to-patient intervention (2 mailings 2 months apart)
Number of subjects: 836
Study 18332291 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 836
Study 22513649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty (VP)
Number of subjects: 125
Study 22513649 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 125
Study 15862729 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic survey (e-survey)
Number of subjects: 202
Study 15862729 — intervention group
Group type: COMPARATOR
Intervention: Postal survey
Number of subjects: 202
Study 12723391 — intervention group
Group type: EXPERIMENTAL
Intervention: VADO approach
Number of subjects: 95
Study 12723391 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation practice (Control)
Number of subjects: 95
Study 10442960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular tenoxicam 20 mg
Number of subjects: 88
Study 10442960 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tenoxicam
Number of subjects: 88
Study 7786822 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 administered as a 30-min i.v. infusion according to 3 different schedules: daily for 3 consecutive days every 3 weeks, weekly for 3 weeks, and once every 3 weeks.
Number of subjects: 235
Study 7786822 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11
Number of subjects: 235
Study 2162276 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive loading
Number of subjects: 12
Study 508162 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 508162 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study 12230222 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (50-100 mg d(-1))
Number of subjects: 42
Study 12230222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200-400 mg d(-1))
Number of subjects: 42
Study 12230222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadiazine (100-150 mg kg d(-1) up to 6 g d(-1))
Number of subjects: 42
Study 12230222 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 29199141 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline
Number of subjects: 292
Study 29199141 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 292
Study 29199141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 27513932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Number of subjects: 116
Study 27513932 — intervention group
Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study 24395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg + Alcohol 0.8 g/kg (HYD + A)
Number of subjects: 24
Study 24395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 80 mg + Alcohol 0.8 g/kg (B80 + A)
Number of subjects: 24
Study 24395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg + Alcohol 0.8 g/kg (CET + A)
Number of subjects: 24
Study 24395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg + Alcohol 0.8 g/kg (B20 + A)
Number of subjects: 24
Study 24395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg alone (ALC)
Number of subjects: 24
Study 24395298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22738884 — intervention group
Group type: EXPERIMENTAL
Intervention: Back App chair
Number of subjects: 12
Study 22738884 — intervention group
Group type: COMPARATOR
Intervention: Standard backless office chair
Number of subjects: 12
Study 22738884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both chairs
Number of subjects: 12
Study 20191662 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental writing tasks
Number of subjects: 0
Study 20191662 — intervention group
Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 0
Study 18549857 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 2386
Study 18549857 — intervention group
Group type: COMPARATOR
Intervention: No history of hypertension
Number of subjects: 2386
Study 18549857 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension with baseline systolic blood pressure <140 mm Hg
Number of subjects: 2386
Study 18549857 — intervention group
Group type: COMPARATOR
Intervention: No history of hypertension with baseline systolic blood pressure <140 mm Hg
Number of subjects: 2386
Study 16902151 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV positivity (detected by EBER-ISH)
Number of subjects: 110
Study 16902151 — intervention group
Group type: COMPARATOR
Intervention: EBV negativity (detected by EBER-ISH)
Number of subjects: 110
Study 16902151 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 110
Study 16902151 — intervention group
Group type: EXPERIMENTAL
Intervention: Age older than 60 years
Number of subjects: 110
Study 16902151 — intervention group
Group type: EXPERIMENTAL
Intervention: High LDH level
Number of subjects: 110
Study 16902151 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV positivity in elderly population
Number of subjects: 110
Study 12806595 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (40 mg/day) for six months
Number of subjects: 9
Study 12806595 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive group
Number of subjects: 9
Study 10817768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track appointment with a 6-week target waiting time
Number of subjects: 100
Study 10817768 — intervention group
Group type: COMPARATOR
Intervention: Ordinary appointment
Number of subjects: 100
Study 8869769 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50
Study 8869769 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 50
Study 1739794 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose of vitamin A supplementation
Number of subjects: 7197
Study 6340411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose high sodium solution (90 mEq/l)
Number of subjects: 51
Study 6340411 — intervention group
Group type: COMPARATOR
Intervention: Sucrose low sodium solution (58 mEq/l)
Number of subjects: 51
Study 6340411 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 51
Study 31578887 — intervention group
Group type: EXPERIMENTAL
Intervention: phacoemulsification + visco-goniosynechialysis + goniotomy
Number of subjects: 61
Study 31578887 — intervention group
Group type: COMPARATOR
Intervention: phacoemulsification + visco-goniosynechialysis
Number of subjects: 61
Study 30612511 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy with internet-based videos for 60 minutes once a week for 3 months
Number of subjects: 32
Study 30612511 — intervention group
Group type: COMPARATOR
Intervention: Control group received unstructured interviews for 25 to 30 minutes during the same period
Number of subjects: 32
Study 30235002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearon criteria (weight loss >5% OR weight loss >2% with either BMI <20 kg/m2 or sarcopenia)
Number of subjects: 69
Study 30235002 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment by oncologist
Number of subjects: 69
Study 30235002 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically cachectic patients
Number of subjects: 69
Study 27075910 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐HFP with BCC strategy implemented by older women leaders
Number of subjects: 1767
Study 27075910 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1767
Study 25243781 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ (olmesartan/amlodipine/hydrochlorothiazide)
Number of subjects: 2690
Study 25243781 — intervention group
Group type: COMPARATOR
Intervention: OLM/AML (olmesartan/amlodipine)
Number of subjects: 2690
Study 22771125 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled cognitive-behavioral (CB) intervention using relaxation, imagery, or distraction exercises delivered via an MP3 player for two weeks.
Number of subjects: 86
Study 22771125 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition for the same two week period.
Number of subjects: 86
Study 20615267 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe (ferrous sulphate) daily
Number of subjects: 164
Study 20615267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe plus 400 μg folic acid daily
Number of subjects: 164
Study 20615267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe plus 2 mg retinol and 1 mg riboflavin daily
Number of subjects: 164
Study 20615267 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 164
Study 17284502 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based tutorial on inhaler technique
Number of subjects: 34
Study 17284502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tutorial)
Number of subjects: 34
Study 16099888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest combined with normoenergetic nutrition
Number of subjects: 10
Study 16099888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet under ambulatory conditions
Number of subjects: 10
Study 16099888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest combined with hypoenergetic diet
Number of subjects: 10
Study 16099888 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (ambulatory)
Number of subjects: 10
Study 12803689 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased salt intake
Number of subjects: 0
Study 12803689 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of triggering factors
Number of subjects: 0
Study 12803689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular volume expansion
Number of subjects: 0
Study 12803689 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive head-up tilt testing
Number of subjects: 0
Study 12803689 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical history
Number of subjects: 0
Study 10469179 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FVIIa (rFVIIa) treatment
Number of subjects: 67
Study 10469179 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FVIIa (rFVIIa) treatment during surgery
Number of subjects: 67
Study 10469179 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during treatment episodes
Number of subjects: 67
Study 7502551 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subsalicylate, metronidazole, tetracycline plus ranitidine)
Number of subjects: 40
Study 7502551 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (omeprazole and amoxicillin)
Number of subjects: 40
Study 7502551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured H. pylori infection (both therapies)
Number of subjects: 40
Study 7502551 — intervention group
Group type: COMPARATOR
Intervention: Persistently infected with H. pylori
Number of subjects: 40
Study 2138684 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac + vitamins B1 (50 mg), B6 (50 mg), B12 (0.25 mg)
Number of subjects: 418
Study 2138684 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (25 mg)
Number of subjects: 418
Study 2138684 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac + vitamins B1, B6, B12
Number of subjects: 418
Study 6103208 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg daily)
Number of subjects: 28
Study 6103208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30807613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg
Number of subjects: 292
Study 30807613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 28105519 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c of 8.0% (64 mmol/mol)
Number of subjects: 117
Study 28105519 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c of 6.0% (42 mmol/mol)
Number of subjects: 117
Study 26683246 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342
Study 26683246 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 342
Study 25157406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 1480
Study 22466021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment plus usual neck exercises (PTcb group)
Number of subjects: 80
Study 22466021 — intervention group
Group type: COMPARATOR
Intervention: Usual neck exercises alone (PT group)
Number of subjects: 80
Study 18688657 — intervention group
Group type: COMPARATOR
Intervention: TAS (tacrolimus, azathioprine, corticosteroids)
Number of subjects: 192
Study 18688657 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS + B (tacrolimus, azathioprine, corticosteroids, and basiliximab)
Number of subjects: 192
Study 17141491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mao-to (0.06 g/kg body wt./dose three times daily)
Number of subjects: 60
Study 17141491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mao-to plus Oseltamivir
Number of subjects: 60
Study 17141491 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (2 mg/kg body wt./dose twice daily)
Number of subjects: 60
Study 15849804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D plus 4D ultrasound (Group 2)
Number of subjects: 100
Study 15849804 — intervention group
Group type: COMPARATOR
Intervention: 2D ultrasound only (Group 1)
Number of subjects: 100
Study 11830606 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (mammography, fecal occult blood detection, chest x-ray)
Number of subjects: 12
Study 11830606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12
Study 11830606 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 12
Study 11830606 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 10069678 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with free NO availability
Number of subjects: 26
Study 10069678 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with NO clamp (using L-NMMA)
Number of subjects: 26
Study 10069678 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with vitamin C co-infusion
Number of subjects: 26
Study 10069678 — intervention group
Group type: COMPARATOR
Intervention: Saline control during angiotensin II infusion
Number of subjects: 26
Study 7628024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg, approximately 1.4 mg.kg‐1 mean) administered at 9:00 pm the night before surgery and at 5:30 am on the morning of surgery
Number of subjects: 100
Study 7628024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7628024 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Lansoprazole
Number of subjects: 100
Study 7628024 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole followed by Placebo
Number of subjects: 100
Study 2035037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic leg brace (Aircast)
Number of subjects: 60